R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 49.6 CNY -4.39% Market Closed
Market Cap: 4.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Total Equity
ÂĄ1.7B
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Equity
ÂĄ54.7B
CAGR 3-Years
14%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Equity
ÂĄ13B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Equity
ÂĄ40.7B
CAGR 3-Years
7%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Equity
ÂĄ20.8B
CAGR 3-Years
7%
CAGR 5-Years
40%
CAGR 10-Years
39%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Equity
ÂĄ5.5B
CAGR 3-Years
144%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
4.8B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
59.36 CNY
Undervaluation 16%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Total Equity?
Total Equity
1.7B CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Total Equity amounts to 1.7B CNY.

What is R&G PharmaStudies Co Ltd's Total Equity growth rate?
Total Equity CAGR 3Y
76%

Over the last year, the Total Equity growth was 10%. The average annual Total Equity growth rates for R&G PharmaStudies Co Ltd have been 76% over the past three years .

Back to Top